Alexion CEO Hantson Tasked With Kicking Growth Momentum Into Gear
Executive Summary
The rare disease specialist’s new CEO is former Baxalta CEO Ludwig Hantson, who takes over the helm immediately after a leadership shakeup coinciding with an audit investigation.
You may also be interested in...
Alexion's Defensive Play Poised To Pay Off
The company's long-acting C5 complement inhibitor ALXN1210 demonstrated non-inferiority to Soliris in a Phase III trial, which should help the company defend against anticipated competition to its blockbuster franchise.
Akari CEO Says Synthetic Royalties May Be Used To Fund Coversin Trials
Akari Therapeutics will explore novel funding options to pay for Phase III trials of Coversin, its lead asset, derived from a native protein discovered in the saliva of the Ornithodoros moubata tick.
Inexperienced Biotech CEOs Impact Investor Confidence – Analyst Research
Median tenure of large cap US biotech CEOs has decreased from 11 years in 2007 to one year in 2017, Leerink analyst Geoffrey Porges determined in an analysis of seven biotechs over 15 years.